Cite
APA Citation
Cooke, K., Estrada, J., Zhan, J., Werner, J., Lee, F., Shetty, A., Smit, M. D., Salvati, M., & Bailis, J. (n.d.). 627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer. Journal for immunotherapy of cancer, 8, A376–A377. http://access.bl.uk/ark:/81055/vdc_100144726627.0x000003